Abstract
Background Perianal fistulizing Crohn’s disease (CD-PAF) is difficult to treat, and several MR scoring systems have been developed to assess treatment response.
Objective To assess the relationship between CD-PAF MR scoring systems and radiologists’ subjective assessment of CD-PAF severity and treatment response on baseline and follow-up pelvic MR.
Methods Retrospective single institution study of consecutive symptomatic patients with CD-PAF patients who underwent pelvic MR before and ≥3 months after initiating biologic therapy during a 10-year period (December 2011 to December 2021). One of four radiologists interpreted baseline and follow-up MRs. Scoring systems included variables in the modified Van Assche index (mVAI), magnetic resonance novel index for fistula imaging in CD (MAGNIFI-CD), and pediatric MR-based perianal Crohn’s disease (PEMPAC) index. For initial and follow-up MR, a 5-point Likert scale assessed severity (1=mild, 3=moderate, 5=marked). On follow-up MR, radiologists evaluated fistula response as 1-improved, 3-stable, or 5-worsened CD-PAF severity. All four study radiologists scored the baseline MR in 20 patients to calculate inter-reader agreement statistics. Interrater reliability was assessed with the Krippendorff α coefficient for categorical variables and intraclass correlation coefficient (ICC) for continuous variables.
Results The final cohort included 96 CD-PAF patients (50 men; mean age=33.0 years) with 192 baseline and follow-up MRs. Moderate to substantial agreement was observed among radiologists for MAGNIFI-CD, mVAI, PEMPAC, and Likert scores (ICC: 0.716, 0.756, 0.535, and 0.679 respectively). Individual components of MR scoring systems had Fair to Substantial agreement (Alpha: 0.195 to 0.730). Significant univariate associations were found between MR scoring systems and radiologists’ Likert severity assessments (p<0.001, Pearson correlation coefficients ≥0.820). In patients meeting criteria for change in disease severity (n=17), all scoring systems demonstrated AUC values ≥0.93.
Conclusion The MR scoring systems for CD-PAF (MAGNIFI-CD, mVAI, and PEMPAC) demonstrated strong associations with radiologists’ subjective assessments of severity and treatment response on baseline and follow-up pelvic MR. Inter-reader agreement of these scoring systems outperformed individual MR factors.
Competing Interest Statement
Potential Competing Interests: SA, RB, AG, JH, DRL, AS, MZ, AG, GB, AE, JA, PM declare no conflicts of interest. PD: has received research support under a sponsored research agreement unrelated to the data in the paper and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Scipher Medicine, Fresenius Kabi, Teva Pharmaceuticals, Landos Pharmaceuticals, Iterative scopes and CorEvitas, LLC. PD and DHB receive research support from an Investigator-Initiated Study from Takeda Pharmaceuticals.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Washington University review board approval gave ethical approval for this work (local IRB #202004277), including a waiver of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support No funding was obtained for this project. Dr. Deepak is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn’s & Colitis Foundation.
Potential Competing Interests: SA, RB, AG, JH, DRL, AS, MZ, AG, GB, AE, JA, PM declare no conflicts of interest.
PD: has received research support under a sponsored research agreement unrelated to the data in the paper and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Roche Genentech, Scipher Medicine, Fresenius Kabi, Teva Pharmaceuticals, Landos Pharmaceuticals, Iterative scopes and CorEvitas, LLC.
PD and DHB receive research support from an Investigator-Initiated Study from Takeda Pharmaceuticals
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
